The investment will help scale the company’s 2910 nm fiber laser platforms, designed for use across all skin types.
Medical technology company Acclaro Medical has raised $23 million in Series B funding to support the global expansion of its fiber laser technologies for skin health and aesthetic treatment.
The round was led by Accelmed Partners, with continued participation from existing investor 3E Bioventures Capital. According to the company, the funding will support the growth of its flagship products—UltraClear and AuraLux—and accelerate development of new technologies in its pipeline.
UltraClear is a 2910 nm cold ablative fiber laser designed to treat multiple layers of skin and address signs of aging. It uses Acclaro’s proprietary 3DIntelliPulse technology and is intended to improve clinical outcomes, reduce patient discomfort, and minimize recovery time. The device is also designed for use across all skin types, including patients historically considered high-risk.
AuraLux, a second product from Acclaro, leverages the same exclusive Cool Pulse technology and broadens accessibility for aesthetic providers and their patients.
“Securing this Series B investment is a powerful testament to our unstoppable team and the tremendous progress that Acclaro has made in a very short period of time,” says Acclaro Medical CEO and co-founder Helen Fang in a release. “This funding empowers us to continue our strong growth and realize our vision of improving the quality of life for people of all skin colors and all ages worldwide.”
Shlomo Assa, president and co-founder of Acclaro Medical, adds in a release, “We are thrilled to have the support of Accelmed as we expand our global and domestic footprint. This Series B funding is a strong vote of confidence in our mission to bring UltraClear and AuraLux to more people pursuing anti-aging solutions for healthier and younger-looking skin.”
The investment will also allow Acclaro to draw on the operational and financial expertise of Accelmed, in addition to the support of 3E Bioventures.
“Acclaro’s unique cold laser fiber technology constitutes a game changer in laser aesthetics with the possibility for aesthetic practices to safely treat all skin types for all major indications using only one device,” says Daniel Cohen, Accelmed’s venture partner, in a release. “Accelmed Partners is thrilled to lead this round of financing and accompany Acclaro’s management in this fantastic journey.”
Photo caption: UltraClear
Photo credit: Acclaro
